Croda International Acquires Avanti Polar Lipids

AbbVie Acquires Capstan Therapeutics

August 19, 2025

Biotechnology

AbbVie has completed its acquisition of Capstan Therapeutics, adding Capstan's lead asset CPTX2309 — an in vivo targeted lipid nanoparticle (tLNP) anti‑CD19 CAR‑T candidate in Phase 1 for B cell‑mediated autoimmune diseases — and a proprietary tLNP RNA delivery platform. The deal strengthens AbbVie's immunology pipeline and expands its in vivo cell‑programming capabilities for RNA payload delivery.

Caldic Acquires Avatar Corporation

September 1, 2022

Food & Beverage

Caldic B.V. has acquired Avatar Corporation, a specialty food-ingredients distributor and custom-formulation manufacturer based in University Park, Illinois. The deal expands Caldic's North American food-industry portfolio and manufacturing capabilities — including custom liquid blends, R&D and onsite rail transloading — to better serve US customers.

Apax Development Acquires Majority Stake in Porsolt

February 21, 2023

Biotechnology

Apax Development, a European private equity firm, has acquired a majority stake in Porsolt SAS, a French preclinical Contract Research Organization (CRO). The investment will support Porsolt's plans to expand services, accelerate hiring (targeting ~40% headcount growth), pursue bolt-on acquisitions in Europe and the US, and extend its global footprint.

Advent International to Acquire Significant Stake in Suven Pharmaceuticals

December 26, 2022

Pharmaceuticals

Advent International has entered into a definitive agreement to acquire a significant stake in Suven Pharmaceuticals from the Jasti family and will make an open offer for an additional 26% of public shares. Advent plans to evaluate a merger of its CDMO and API platform company, Cohance Lifesciences, with Suven to create a scaled end-to-end CDMO + merchant API powerhouse serving pharma and specialty chemical markets, subject to board and regulatory approvals.

Danaher Acquires Precision NanoSystems

June 1, 2021

Biotechnology

Danaher Corporation has acquired Vancouver-based Precision NanoSystems (PNI), a developer of lipid nanoparticle delivery technologies and microfluidic manufacturing platforms for genetic medicines. PNI will join Danaher's Life Sciences platform to expand its capabilities in mRNA and genetic-medicine development and complement existing portfolio companies such as Cytiva and Pall.

Apollo Funds to Acquire Covis Pharma from Cerberus

February 6, 2020

Pharmaceuticals

Funds managed by affiliates of Apollo Global Management have agreed to acquire Covis Pharma BV from an affiliate of Cerberus Capital Management. Terms were not disclosed; the transaction is expected to close by the end of Q1 2020 and aims to accelerate Covis's global expansion and build out its respiratory and specialty pharma franchises.